First / Second class postgraduate degree, including the integrated PG degrees with one year experience or PhD. Molecular Biology, Cancer Biology, Biotechnology, Pharmacology, Pathology, Life Sciences.
ECHS invites applications to engage following Medical, Para Medical. & Non Medical Staff on contractual basis in ECHS Polyclinic Haldwani for a period of one year renewable for additional period of one year, till attaining the maximum age subject to performance of candidates.
Person should have the worked on Peptide Manufacturing & Peptide Synthesis and Exposure to Peptide Synthesis, purification, filtration and drying processes and Peptides synthesis, Peptide purification, Lyophilization.
Eli Lilly has provided new insights into retatrutide, its investigational medicine that is attracting significant attention for its potential to treat obesity, type 2 diabetes, and several obesity-related health conditions. While the therapy remains under clinical development and is not yet approved for public use, ongoing research suggests it could become one of the most impactful treatments in the rapidly growing obesity care market.
Researchers at Mass General Brigham have developed a promising blood test that could help physicians identify head and neck cancer patients at higher risk of disease recurrence and poorer survival outcomes, potentially enabling more personalized treatment strategies and follow-up care.
Merck has announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), as well as the newly approved subcutaneous formulation KEYTRUDA QLEx™, in combination with WELIREG® (belzutifan) for the adjuvant treatment of certain patients with renal cell carcinoma (RCC), the most common form of kidney cancer.